Physician profile
Bart L Main
NPI 1689770604
$2,325.15
in general payments reported to CMS, 2019-2025
19 companies · $1,354 in 2025
The $1,354 reported for 2025 was more than what 89% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $108 · 2021: $221 · 2023: $283 · 2024: $359 · 2025: $1,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,821 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,820.72 |
| Education | $175.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $405.03 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $308.88 | 2021-2025 | Invega Sustenna, Spravato |
| Teva Pharmaceuticals USA, INC. | $298.27 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $267.48 | 2025 | Cobenfy |
| Abbvie INC. | $144.62 | 2024-2025 | |
| Axsome Therapeutics, INC. | $144.61 | 2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $130.24 | 2021 | |
| Vanda Pharmaceuticals INC. | $123.07 | 2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $107.82 | 2020 | |
| Alkermes, INC. | $94.38 | 2023-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $73.91 | 2024-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $56.33 | 2024-2025 | Ingrezza |
| Luye Pharma (USA) LTD. | $36.63 | 2025 | Erzofri Extended-Release |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.06 | 2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $30.17 | 2024 | Qelbree |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $28.26 | 2023 | Trintellix |
| Sage Therapeutics, LLC | $19.26 | 2024 | |
| Collegium Pharmaceutical, INC. | $14.47 | 2025 | Jornay Pm |
| Corium, LLC | $8.66 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bart Main listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.